These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 22819360

  • 1. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B, Langleben D, Hirsch AM, Schlesinger RD, Eisenberg MJ, Joyal D, Blenkhorn F, Lesenko L.
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [Abstract] [Full Text] [Related]

  • 2. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H, Hara T, Tsuji M, Saito A, Minatsuki S, Inaba T, Amiya E, Hosoya Y, Hatano M, Morita H, Yao A, Kinugawa K, Komuro I.
    Int Heart J; 2020 Jun; 61(4):799-805. PubMed ID: 32728000
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P, Coghlan G.
    Drugs; 2008 Jun; 68(12):1635-45. PubMed ID: 18681488
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
    Steiner MK, Preston IR.
    Vasc Health Risk Manag; 2008 Jun; 4(5):943-52. PubMed ID: 19183742
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A review of pulmonary arterial hypertension: role of ambrisentan.
    Barst RJ.
    Vasc Health Risk Manag; 2007 Jun; 3(1):11-22. PubMed ID: 17583171
    [Abstract] [Full Text] [Related]

  • 11. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
    Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, Kawut SM, Halpern SD.
    Chest; 2012 Jan; 141(1):20-26. PubMed ID: 21940766
    [Abstract] [Full Text] [Related]

  • 12. Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study.
    Dawson A, Reddecliffe S, Coghlan C, Schreiber BE, Coghlan JG.
    Eur J Cardiovasc Nurs; 2018 Oct; 17(7):612-618. PubMed ID: 29641223
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
    Safdar Z.
    Vasc Health Risk Manag; 2011 Oct; 7():119-24. PubMed ID: 21468170
    [Abstract] [Full Text] [Related]

  • 15. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
    Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ.
    J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
    [Abstract] [Full Text] [Related]

  • 16. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N, Derk CT.
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
    Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C.
    Am J Cardiol; 2011 Jul 15; 108(2):302-7. PubMed ID: 21545989
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Role of ambrisentan in the management of pulmonary hypertension.
    Hrometz SL, Shields KM.
    Ann Pharmacother; 2008 Nov 15; 42(11):1653-9. PubMed ID: 18957622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.